Search Results - "Rudick, RA"

Management of Multiple Sclerosis by Rudick, Richard A, Cohen, Jeffrey A, Weinstock-Guttman, Bianca, Kinkel, Revere P, Ransohoff, Richard M

“…Multiple sclerosis is a common disease of the central nervous system affecting approximately 1 million young adults, mostly women, worldwide. 1 It is…”
Get full text

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire by Benedict, RHB, Duquin, JA, Jurgensen, S, Rudick, RA, Feitcher, J, Munschauer, FE, Panzara, MA, Weinstock-Guttman, B

“…Background Brief cognitive performance tests and self-report measures of neuropsychological symptoms have been proposed for screening purposes in multiple…”
Get full text

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures by Ontaneda, D, LaRocca, N, Coetzee, T, Rudick, RA

“…This article describes proceedings from a meeting of the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures (the TF). The TF…”
Get full text

Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis by Rudick, Richard A, Stuart, William H, Calabresi, Peter A, Confavreux, Christian, Galetta, Steven L, Radue, Ernst-Wilhelm, Lublin, Fred D, Weinstock-Guttman, Bianca, Wynn, Daniel R, Lynn, Frances, Panzara, Michael A, Sandrock, Alfred W

“…In this randomized trial involving patients with relapsing multiple sclerosis who had had relapses despite treatment with interferon, natalizumab in…”
Get full text

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis by Fisher, E, Nakamura, K, Lee, J-C, You, X, Sperling, B, Rudick, RA

“…Background: Changes in gray matter (GM) volume may be a useful measure of tissue loss in multiple sclerosis (MS). Objectives: To investigate the rate,…”
Get full text

Defining interferon β response status in multiple sclerosis patients by Rudick, Richard A., Lee, Jar-Chi, Simon, Jack, Ransohoff, Richard M., Fisher, Elizabeth

“…IFN‐β is effective in reducing relapses and magnetic resonance imaging (MRI) lesions in multiple sclerosis (MS). It is assumed that individual therapeutic…”
Get full text

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON [beta]: A SYSTEMATIC REVIEW AND META-ANALYSIS by Dobson, R, Rudick, RA, Giovannoni, G

“…Objective Interferon-β (IFN-β) reduces relapse rates in multiple sclerosis; however clinical response varies between subjects. Can MRI be reliably used to…”
Get full text

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study by Bermel, RA, Weinstock-Guttman, B., Bourdette, D., Foulds, P., You, X., Rudick, RA

“…Disease-modifying drugs are initiated early and continued for years in patients with multiple sclerosis. Long-term tolerability and impact are not known. The…”
Get full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS by RUDICK, R. A, FISHER, E, LEE, J.-C, SIMON, J, JACOBS, L

Get full text

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS by ZIVADINOV, R, RUDICK, R. A, DE MASI, R, NASUELLI, D, UKMAR, M, POZZI-MUCELLI, R. S, GROP, A, CAZZATO, G, ZORZON, M

“…IV methylprednisolone (IVMP) has been used to treat relapses in patients with relapsing-remitting (RR) MS, but its effect on disease progression is not known…”
Get full text

Eight-year follow-up study of brain atrophy in patients with MS by FISHER, E, RUDICK, R. A, SIMONIAN, N. A, SIMON, J. H, CUTTER, G, BAIER, M, LEE, J.-C, MILLER, D, WEINSTOCK-GUTTMAN, B, MASS, M. K, DOUGHERTY, D. S

“…To characterize whole-brain atrophy in relapsing-remitting MS (RRMS) patients over an 8-year period. The specific goals of this study were to determine if…”
Get full text

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS by Cohen, J A, Cutter, G R, Fischer, J S, Goodman, A D, Heidenreich, F R, Kooijmans, M F, Sandrock, A W, Rudick, R A, Simon, J H, Simonian, N A, Tsao, E C, Whitaker, J N

“…Interferon beta-1a (IFNbeta-1a, Avonex) is efficacious in relapsing forms of MS. Studies of other IFNbeta preparations in secondary progressive MS (SPMS)…”
Get full text

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON β: A SYSTEMATIC REVIEW AND META-ANALYSIS by Dobson, R, Rudick, RA, Giovannoni, G

“…Objective Interferon-β (IFN-β) reduces relapse rates in multiple sclerosis; however clinical response varies between subjects. Can MRI be reliably used to…”
Get full text

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis by BAIER, M. L, CUTTER, G. R, RUDICK, R. A, MILLER, D, COHEN, J. A, WEINSTOCK-GUTTMAN, B, MASS, M, BALCER, L. J

“…To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis…”
Get full text

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment by Fischer, J S, Rudick, R A, Cutter, G R, Reingold, S C

“…Clinical outcome assessment in Multiple Sclerosis (MS) is challenging due to the diversity and fluctuating nature of MS symptoms. Traditional clinical scales…”
Get full text

Axonal loss in normal-appearing white matter in a patient with acute MS by BJARTMAR, C, KINKEL, R. P, KIDD, G, RUDICK, R. A, TRAPP, B. D

“…Brain imaging studies detect abnormalities in normal-appearing white matter in patients with MS. To investigate the histopathologic basis for these changes in…”
Get full text

Development of a multiple sclerosis functional composite as a clinical trial outcome measure by Cutter, Gary R., Baier, Monika L., Rudick, Richard A., Cookfair, Diane L., Fischer, Jill S., Petkau, John, Syndulko, Karl, Weinshenker, Brian G., Antel, Jack P., Confavreux, Christian, Ellison, George W., Lublin, Fred, Miller, Aaron E., Rao, Stephen M., Reingold, Stephen, Thompson, Alan, Willoughby, Ernest

“…The primary clinical outcome measure for evaluating multiple sclerosis in clinical trials has been Kurtzke's expanded disability status scale (EDSS). New…”
Get full text

Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

“…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
Get full text

Association of fatigue and brain atrophy in multiple sclerosis by Marrie, Ruth Ann, Fisher, Elizabeth, Miller, Deborah M., Lee, Jar-Chi, Rudick, Richard A.

“…Functional imaging studies have demonstrated a relationship between fatigue and altered cerebral activation patterns in multiple sclerosis patients, but no…”
Get full text